Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s stock price hit a new 52-week low during trading on Thursday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 10000 shares traded. The stock had previously closed at C$0.02.
Quest PharmaTech Stock Performance
The business has a fifty day moving average price of C$0.03 and a 200 day moving average price of C$0.03. The company has a market capitalization of C$3.38 million, a PE ratio of 0.67 and a beta of -0.07. The company has a debt-to-equity ratio of 4.35, a quick ratio of 0.52 and a current ratio of 0.40.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Featured Stories
- Five stocks we like better than Quest PharmaTech
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
- Sociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the Show
- Forget Chips: These 3 Stocks Are Building the AI Data Center Boom
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
